Article

Feasibility of DPYD Genotyping in Australian Cancer Patients

2023-06-09

Abstract excerpt

<h4>Background: </h4> Fluoropyrimidine (FP) chemotherapies are widely prescribed for solid organ malignancies, including colorectal, gastrointestinal, breast and head and neck cancers. They are prescribed for over 10,000 Australian cancer patients per year. Between 10-40% of patients experience serious (grade 3-5) toxicities that can result in hospitalisation, intensive care admission and even death. Dihydropyrimi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e119e1be-cb9f-5804-a023-34f95b14eb96
DOI: 10.21203/rs.3.rs-2838793/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Feasibility of DPYD Genotyping in Australian Cancer PatientsDOI 10.21203/rs.3.rs-2838793/v1Read

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.Semantic proximity Read

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity Read

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Semantic proximity Read

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.Semantic proximity Read

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.Semantic proximity Read

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity Read

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.Semantic proximity Read

Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.Semantic proximity Read

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in GreeceSemantic proximity Read